Syndrome de l’intestin irritable post-infectieux

  • P. Ducrotté

Résumé

Le syndrome de l’intestin irritable (SII) est le plus fréquent des troubles fonctionnels intestinaux. Sa prévalence dans la population générale est chiffrée entre 10 à 12 % avec les critères de définition actuels avec une atteinte féminine prédominante (sex-ratio: 2/1) [1]. Il se manifeste par une douleur ou un inconfort chronique de l’abdomen qui survient en dehors de toute anomalie anatomique caractérisée et qui s’associe à des perturbations du transit intestinal (constipation, diarrhée ou alternance des deux) qui sont plus marquées lors des poussées douloureuses. Le SII est une maladie multifactorielle mais les facteurs déclenchants des symptômes demeurent le plus souvent mal identifiés.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Longstreh GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130: 1480–91.CrossRefGoogle Scholar
  2. 2.
    Stewart GT. Post-dysenteric colitis. BMJ 1950;i:405–9.CrossRefGoogle Scholar
  3. 3.
    Chaudary NA, Truelove SC. The irritable colon syndrome. Quart J Med 1962;123:307–22.Google Scholar
  4. 4.
    McKendrick MW, Read NW. Irritable bowel syndrome post salmonella infection. J Infection 1994;29:1–3.CrossRefGoogle Scholar
  5. 5.
    Neal KR, Hebden J, Spiller R. Prevalence of gastro-intestinal symptoms six months after bacterial gastro-enteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779–82.PubMedGoogle Scholar
  6. 6.
    Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565–6.PubMedGoogle Scholar
  7. 7.
    Marshall JK, Thabane M, Garg AX, Clark W, Salvadori M, Collins SM and the Walkertone Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterbone outbreak of bacterial dysentery. Gastroenterology 2006;131:445–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Mearin F, Perez-Oliveras M, Perello A et al. Dyspepsia and irritable bowel syndrome after a salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129: 98–104.CrossRefPubMedGoogle Scholar
  9. 9.
    Thabane M, Kottachchi DT, Marshall JK. Systematic reviewand meta-analysis: the incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26: 535–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Thabane M, Simunovic M, Aktar-Danesh N, Marshall JK. Development and validation of a risk score for postinfectious irritable bowel syndrome. Am J Gastroenterol 2009;104: 2267–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Morken MH, Lind RA, Valeur J, Wilhelmsen I, Berstad A. Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: a case control study. Scand J Gastroenterol 2009;44:308–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Marshall JK, Thabane M, Garg AX. Post infectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5:457–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Mot 2004;16:135–42.CrossRefGoogle Scholar
  14. 14.
    Spiller RC, Garsed K. Infection, inflammation, and the irritable bowel syndrome. Dig Liv Dis 2009;41:916.CrossRefGoogle Scholar
  15. 15.
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993;38:1590–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007;19 Suppl 2:25–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastoenterology 2004;126:693–702.CrossRefGoogle Scholar
  21. 21.
    Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Barbara G, Stanghellini V, Brandi G et al. Interactions between commensal bacteria and gut sensori-motor function in health and disease. Am J Gastroenterol 2005;100:2560–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288–94.CrossRefPubMedGoogle Scholar
  24. 24.
    Demaude J, Levêque M, Chaumaz G et al. Acute stress increases colonic paracellular permeabililty in mice through a mast cell-independent mechanism: involvement of pancreatic trypsin. Life Sci 2009;84:847–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel syndrome after infectious diarrhoea. Lancet 1996;347:150–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Van der Veek PP, Van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Pole of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Villami AC, Saito Y, Lemire M et al. Validation of genetic risk factors for post-infectious IBS in patients with sporadic IBS. Gastroenterology 2009;136:A 404.Google Scholar
  29. 29.
    Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Ducrotté P. Syndrome de l’intestin irritable: options thérapeutiques médicamenteuses et diététiques actuelles. Gastroenterol Clin Biol 2009;33(suppl 1):568–78.Google Scholar
  31. 31.
    Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30:245–52.CrossRefPubMedGoogle Scholar
  32. 32.
    Dunlop SP, Jenkins D, Neal KR et al. Randomized, double-blind, placebocontrolled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:77–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Bafutto M, Almeida JR, Almeida RC. Treatment of postinfectious irritable bowel syndrome and non infective irritable bowel syndrome with mesalazine. Gastroenterology 2008;134: A672.Google Scholar
  34. 34.
    McFarland LV, Dublin S. meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14: 2650–61.CrossRefPubMedGoogle Scholar
  35. 35.
    Spiller R. Probiotics: an ideal antiinflammatory treatment for IBS? Gastroenterology 2005;128:783–5.CrossRefPubMedGoogle Scholar
  36. 36.
    O’Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2010

Authors and Affiliations

  • P. Ducrotté
    • 1
  1. 1.Département d’hépato-gastroentérologie et de nutrition CHRUHôpital Charles NicolleRouen Cedex

Personalised recommendations